Zobrazeno 1 - 10
of 93
pro vyhledávání: '"C. Sederholm"'
Autor:
D. Perry, C. Sederholm
Adapting Poe is a collection of essays that explores the way Edgar Allan Poe has been adapted over the last hundred years in film, comic art, music, and literary criticism. A major theme that pervades the study concerns the more recent re-imaginings
Publikováno v:
British Journal of Cancer
We report a pilot study on the Fas receptor (APO-1, CD95) in vivo in 15 human squamous cell (non-small) carcinomas and ten normal bronchial specimens. The principal aim was to investigate whether the so-called death receptor, Fas, is present in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5505a4bba3ea35acd133e1223ff814dc
https://doi.org/10.1038/bjc.1997.359
https://doi.org/10.1038/bjc.1997.359
Autor:
Rolf A. Stahel, Karin Mattson, N. v. Walree, K. Liippo, Joachim von Pawel, Peter Drings, P. Kellokumpu-Lehtinen, Christian Manegold, W. W. ten Bokkel-Huinink, C. Sederholm, S. Ricci, Gunnar Wagenius, B. Bergman, W. Dornoff, Assad Chemaissani
Publikováno v:
Annals of Oncology. 8:525-529
Summary Background This randomised study was designed to determine the response rate, survival and toxicity of single-agent gemcitabine and cisplatin-etoposide in chemo-naive patients with locally advanced or metastatic non-small-cell lung cancer. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab5b5e1549977eb294f5e38923e8316
https://doi.org/10.1023/a:1008207731111
https://doi.org/10.1023/a:1008207731111
Autor:
J, Nyman, S, Friesland, A, Hallqvist, M, Seke, S, Bergström, L, Thaning, B, Lödén, C, Sederholm, G, Wagenius
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 65(1)
A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f0ec465dc5277817e4fbc0448bcbb14
https://pubmed.ncbi.nlm.nih.gov/19081652
https://pubmed.ncbi.nlm.nih.gov/19081652
Autor:
B. Bergman, Andreas Hermes, U. Aasebø, Jan Vilsvik, Sverre Sörenson, L. Ek, R. Bremnes, S. Fluge, L. Thaning, C. Sederholm, S. Sundstrøm
Publikováno v:
Pneumologie. 62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4085025e02a77d6eadcbbb800de09246
https://doi.org/10.1055/s-2008-1074396
https://doi.org/10.1055/s-2008-1074396
Autor:
M, Helsing, L, Thaning, C, Sederholm, K, Lamberg, J E, Martinsson, L, Ek, T, Månsson, L, Andersson, U, Hero, D, Anjedani, G, Svennson
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 24(2)
The primary aim of this phase II study was to determine the response rate of a combination of paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC) in a multicentre setting. The secondary aim was to determine time to progression (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::009bce80ba500d1b9efdc876f5be01c5
https://pubmed.ncbi.nlm.nih.gov/10444061
https://pubmed.ncbi.nlm.nih.gov/10444061
Autor:
C, Manegold, P, Drings, J, von Pawel, S, Ricci, W, Dornoff, N, van Walree, W, ten Bokkel Huinink, A, Chemaissani, P, Stahel, B, Bergman, G, Wagenius, C, Sederholm, K, Mattson, K, Liippo, P, Kellokumpu-Lehtinen
Publikováno v:
Seminars in oncology. 24(3 Suppl 8)
This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9a235a236f4aaae8b778fd81d990c46
https://pubmed.ncbi.nlm.nih.gov/9207310
https://pubmed.ncbi.nlm.nih.gov/9207310
Autor:
Martin Reck, C. Caspar, R. Perng, S. Allan, Robert Pirker, M. Boyer, H. Groen, C. Sederholm, H. Riska, P. Berzinec
Publikováno v:
Journal of Clinical Oncology. 24:7190-7190
7190 Background: Erlotinib is an orally active and selective inhibitor of HER1/EGFR tyrosine kinase. In the BR.21 phase III trial, erlotinib significantly prolonged survival, delayed symptom progression, and improved quality of life in NSCLC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc950ed7cba4da177f058438458ad86
https://doi.org/10.1200/jco.2006.24.18_suppl.7190
https://doi.org/10.1200/jco.2006.24.18_suppl.7190
Autor:
Amache-Vaccaro, Rana1,2 (AUTHOR), Bebe, Siziwe1,2 (AUTHOR), Prakash, Ravi1 (AUTHOR) ravi.prakash@carleton.ca
Publikováno v:
Soft Materials. 2023, Vol. 21 Issue 1, p117-128. 12p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.